Publications by authors named "Kisakova L"

Although mRNA vaccines encapsulated in lipid nanoparticles (LNPs) have demonstrated a safety profile with minimal serious adverse events in clinical trials, there is opportunity to further reduce mRNA reactogenicity. The development of naked mRNA vaccines could improve vaccine tolerability. Naked nucleic acid delivery using the jet injection method may be a solution.

View Article and Find Full Text PDF

The removal of double-stranded RNA (dsRNA) contaminants during in vitro mRNA synthesis is one of the technological problems to be solved. Apparently, these contaminants are the result of the T7 RNA polymerase side activity. In this study, we used a modified method of mRNA purification based on the selective binding of dsRNA to cellulose in ethanol-containing buffer.

View Article and Find Full Text PDF

We studied a needle-free jet injection delivery of an experimental mRNA vaccine encoding the receptor-binding domain of the SARS-CoV-2 S protein (mRNA-RBD). Immunization of BALB/c mice with mRNA-RBD by a needle-free jet injector induced high levels of antibodies with virus-neutralizing activity and a virus-specific T-cell response. The immune response was low in the group of mice that received intramuscular injection of mRNA-RBD.

View Article and Find Full Text PDF
Article Synopsis
  • The H5N8 avian influenza virus poses a risk to bird populations and potential human health concerns, necessitating the development of a safe and effective vaccine.
  • Researchers created an experimental pVAX-H5 DNA vaccine that encodes a modified version of the virus's hemagglutinin and tested it on mice, resulting in a strong antibody and T-cell response.
  • Both liquid and lyophilized versions of the pVAX-H5 vaccine provided complete protection for mice against lethal influenza A virus challenges, showing promise as a candidate for combating H5N8.
View Article and Find Full Text PDF

In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus.

View Article and Find Full Text PDF

A promising approach to the development of new means for preventing infection caused by tick-borne encephalitis virus can be DNA vaccines encoding polyepitope T-cell immunogens. A DNA vaccine pVAX-AG4-ub encoding an artificial polyepitope immunogen that includes cytotoxic and T-helper epitopes from the NS1, NS3, NS5, and E proteins of the tick-borne encephalitis virus has been obtained. The developed construct ensured the synthesis of the corresponding mRNAs in transfected eukaryotic cells.

View Article and Find Full Text PDF

Introduction: Nucleic acids represent a promising platform for creating vaccines. One disadvantage of this approach is its relatively low immunogenicity. Electroporation (EP) is an effective way to increase the DNA vaccines immunogenicity.

View Article and Find Full Text PDF

An artificial T-cell immunogen consisting of conserved fragments of different proteins of the SARS-CoV-2 virus and its immunogenic properties were studied in BALB/c mice. To create a T-cell immunogen, we used an approach based on the design of artificial antigens that combine many epitopes from the main proteins of the SARS-CoV-2 virus in the one molecule. The gene of the engineered immunogen protein was cloned as part of the pVAX1 plasmid in two versions: with an N-terminal ubiquitin and without it.

View Article and Find Full Text PDF

DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in 2020, and a DNA vaccine (Zydus Cadila, India), in 2021. They display unique benefits in the current COVID-19 pandemic.

View Article and Find Full Text PDF
Article Synopsis
  • The monkeypox virus outbreak outside Africa in 2022 has highlighted the urgent need for immunization, which could be achieved using a first-generation smallpox vaccine licensed in Russia.
  • Current guidelines recommend transepidermal inoculation (skin scarification), but this method has reliability issues, prompting the exploration of intradermal (i.d.) injection as an alternative vaccination technique.
  • A study compared these two methods in mice, finding no significant difference in antibody responses, but a stronger T-cell immune response with i.d. injection; both methods provided protection against cowpox, while i.d. immunization resulted in a 50% survival rate against a lethal strain of ectromelia virus.
View Article and Find Full Text PDF

Vaccination against SARS-CoV-2 and other viral infections requires safe, effective, and inexpensive vaccines that can be rapidly developed. DNA vaccines are candidates that meet these criteria, but one of their drawbacks is their relatively weak immunogenicity. Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc.

View Article and Find Full Text PDF